[시장보고서]유럽의 차세대 시퀀싱(NGS) 시장

유럽의 차세대 시퀀싱(NGS) 시장 - 분석 및 예측(2023-2033년)

Europe Next Generation Sequencing (NGS) Market: Analysis and Forecast, 2023-2033

상품코드 : 1419007

리서치사 : BIS Research Inc.

발행일 : 2024년 01월

페이지 정보 : 영문

라이선스 & 가격 (부가세 별도)

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

유럽의 차세대 시퀀싱(NGS) 시장 규모는 2023년 17억 1,000만 달러, 2033년 57억 2,000만 달러에 달할 것으로 예상되며, 2023-2033년의 예측 기간 동안 12.83%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다.

차세대 시퀀싱(NGS) 시장은 주로 몇 가지 중요한 요인에 의해 성장하고 있습니다. 여기에는 게놈 시퀀싱과 관련된 비용 감소, 종양학에서 NGS의 유망한 응용, 집단 시퀀싱 연구의 보급, 헬스케어에서 NGS의 통합에 대한 정부의 지원, 다른 시퀀싱 방법과 비교했을 때 NGS 기술의 우수한 특성 등이 포함됩니다.

주요 시장 통계
예측 기간	2023년-2033년
2023년 평가	17억 1,000만 달러
2033년 전망	57억 2,000만 달러
CAGR	12.83%

유럽의 차세대 시퀀싱(NGS) 시장은 특히 라이브러리 준비 및 시퀀싱 분야에서 크게 성장하고 있습니다. 라이브러리 준비는 DNA 또는 RNA의 단편화, 증폭 및 인덱싱이라는 중요한 단계를 포함하며 NGS 워크플로우의 기본 요소입니다. 유전체 연구, 임상 진단 및 개인 맞춤형 의료에서 NGS의 응용이 확대됨에 따라, 높은 처리량과 효율적인 라이브러리 준비 키트 및 시스템에 대한 수요가 증가하는 것이 시장 특징입니다.

라이브러리 준비에 이은 시퀀싱 단계도 마찬가지로 중요합니다. 유럽의 NGS 시장은 정확하고 신속한 시퀀싱 결과를 제공하는 능력으로 인해 Illumina 및 Oxford Nanopore 기술을 포함한 고급 시퀀싱 플랫폼의 채택이 증가하고 있는 것이 특징입니다. 이러한 성장은 헬스케어, 농업, 미생물학 등 다양한 분야에서 유전체 분석에 대한 수요가 증가함에 따라 촉진되고 있으며, 유럽의 NGS 역량 향상에 있어 라이브러리 준비 및 시퀀싱 제품이 매우 중요한 역할을 하고 있음을 보여줍니다.

이 보고서는 유럽의 차세대 시퀀싱(NGS) 시장을 조사했으며, 시장 개요와 함께 제품별, 처리량별, 기술 유형별, 용도별, 국가별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

시장 전망
업계 전망
- NGS : 개요
- 과거 동향
- 각종 기술 비교 분석
- NGS 시장 : 개요
- 신흥 NGS 기술
- 현재의 시장 시나리오
- COVID-19의 NGS 시장에 대한 영향
- 공급망 분석
- 조사 출판물
- 주요 인사이트
- 가격 분석
비즈니스 역학
- 영향 분석
- 비즈니스 촉진요인
- 비즈니스 억제요인
- 비즈니스 기회

제2장 유럽

유럽 NGS 시장
- 개요
- 유럽 법적 요건과 프레임워크
- 시장 역학
- 주요 유통업체
- 게놈 프로젝트
- 금액별 시장 규모와 예측

제3장 시장 - 경쟁 벤치마킹과 기업 개요

경쟁 구도
시장 점유율 분석
NGS 시장 성장 점유율 분석(최종사용자별)
NGS 시장 성장 점유율 분석(throughput별)
기업 개요
- Oxford Nanopore Technologies plc.
- Qiagen N.V.
- F. Hoffmann-La Roche Ltd
- Centogene N.V.
신규 기업 현황
- Alithea Genomics

LSH

영문 목차

영문목차

“The Europe Next Generation Sequencing (NGS) Market Expected to Reach $5.72 Billion by 2033.”

Introduction to Europe Next Generation Sequencing (NGS) Market

The Europe NGS market was valued at $1.71 billion in 2023 and is expected to reach $5.72 billion by 2033, growing at a CAGR of 12.83% during the forecast period 2023-2033. The Next Generation Sequencing (NGS) market is experiencing growth primarily due to several key factors. These include the declining expenses associated with genome sequencing, the promising applications of NGS in oncology, the increasing prevalence of population-wide genomic research, governmental support for the integration of NGS in healthcare, and the superior attributes of NGS technology when compared to other sequencing methods.

KEY MARKET STATISTICS
Forecast Period	2023 - 2033
2023 Evaluation	$1.71 Billion
2033 Forecast	$5.72 Billion
CAGR	12.83%

Market Introduction

The Europe Next Generation Sequencing (NGS) market, specifically within the library preparation and sequencing segments, is witnessing substantial growth. Library preparation involves the crucial steps of DNA or RNA fragmentation, amplification, and indexing, making it a fundamental component of NGS workflows. In this context, the market is characterized by the increasing demand for high-throughput and efficient library preparation kits and systems, driven by the expanding applications of NGS in genomics research, clinical diagnostics, and personalized medicine.

The sequencing step, which follows library preparation, is equally significant. Europe's NGS market is marked by a rising adoption of advanced sequencing platforms, including Illumina and Oxford Nanopore technologies, owing to their ability to deliver accurate and rapid sequencing results. This growth is fueled by the escalating need for genomic analysis in various fields, such as healthcare, agriculture, and microbiology, highlighting the pivotal role of library preparation and sequencing products in advancing NGS capabilities in the European region.

Market Segmentation:

Segmentation 1: by Offering

Consumables
- Library Preparation Kits
- Sequencing Kits
Equipment
Services

Segmentation 2: by Throughput

High- and Ultra-High-Throughput
Medium-Throughput
Low-Throughput

Segmentation 3: by Technology Type

Sequencing by Synthesis
In Torrent Semiconductor Sequencing
Single Molecule Real-Time Sequencing
Nanopore Sequencing Technology
Other Technologies

Segmentation 4: by Application

Clinical Diagnostics
- Oncology
- Non-Oncology
Research
- Oncology
- Non-Oncology

Segmentation 5: by Country

Germany
U.K.
France
Italy
Spain
Rest-of-Europe

How can this report add value to an organization?

Type: The Europe NGS market has been segmented based on various categories, such as offerings, throughput, and platform, among others. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe NGS market is consolidated, with a few players accounting for most of the market share. Key players in the Europe NGS market analyzed and profiled in the study involve established players that offer various kinds of NGS platforms, consumables, and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Key Companies Profiled:

Oxford Nanopore Technologies plc
Qiagen N.V.
F. Hoffmann-La Roche Ltd.

Centogene N.V.
Alithea Genomics

Executive Summary

Scope of the Study

Research Methodology

1. Markets

1.1. Market Outlook
- 1.1.1. Product Definition
- 1.1.2. Inclusion and Exclusion Criteria
- 1.1.3. Key Findings
1.2. Industry Outlook
- 1.2.1. NGS: Overview
- 1.2.2. Historical Trends
- 1.2.3. Comparative Analysis of Various Technologies
- 1.2.4. NGS Market: Overview
- 1.2.5. Emerging NGS Technologies
  - 1.2.5.1. In-Situ Sequencing
  - 1.2.5.2. Microscopy-Based Sequencing
  - 1.2.5.3. Future of Ultra-High Throughput NGS
- 1.2.6. Current Market Scenario
  - 1.2.6.1. For Researchers
  - 1.2.6.2. For Diagnostics
- 1.2.7. COVID-19 Impact on the NGS Market
- 1.2.8. Supply Chain Analysis
  - 1.2.8.1. Key Entities in Supply Chain
- 1.2.9. Research Publications
- 1.2.10. Primary Insights
- 1.2.11. Pricing Analysis
1.3. Business Dynamics
- 1.3.1. Impact Analysis
- 1.3.2. Business Drivers
  - 1.3.2.1. Decreasing Cost of Genome Sequencing
  - 1.3.2.2. Potential of NGS in the Field of Oncology Research and as a Companion Diagnostic for Oncology in Clinical Settings
  - 1.3.2.3. Growing Number of Population-Wide Sequencing Studies and Government Initiatives to Integrate NGS in Healthcare
  - 1.3.2.4. Advantages of NGS Technology over Other Technologies
- 1.3.3. Business Restraints
  - 1.3.3.1. Concerns Surrounding the Privacy of Patient Genomic Data
  - 1.3.3.2. Lack of Complete Reimbursement Coverage for NGS Testing
- 1.3.4. Business Opportunities
  - 1.3.4.1. Evolving Regulatory Landscape for Clinical NGS
  - 1.3.4.2. Growing Number of Gene Mutations across Various Diseases

2. Europe

2.1. Europe NGS Market
- 2.1.1. Overview
- 2.1.2. Legal Requirements and Framework in Europe
- 2.1.3. Market Dynamics
  - 2.1.3.1. Impact Analysis
- 2.1.4. Key Distributors
- 2.1.5. Genome Projects
- 2.1.6. Market Sizing and Forecast, by Value
  - 2.1.6.1. Europe NGS Market (by Offering), by Value
    - 2.1.6.1.1. Europe NGS Market (Equipment), by Value
      - 2.1.6.1.1.1. Europe NGS Market (Equipment, by Company), by Value
      - 2.1.6.1.1.1.1. Europe NGS Market (Equipment, by Illumina, Inc.), by Value
      - 2.1.6.1.1.1.2. Europe NGS Market (Equipment, by Thermo Fisher Scientific Inc.), by Value
      - 2.1.6.1.1.1.3. Europe NGS Market (Equipment, by Pacific Biosciences of California, Inc.), by Value
      - 2.1.6.1.1.1.4. Europe NGS Market (Equipment, by Oxford Nanopore Technologies plc.), by Value
    - 2.1.6.1.2. Europe NGS Market (Equipment), by Volume
    - 2.1.6.1.3. Europe NGS Market (by Throughput), by Value
    - 2.1.6.1.4. Europe NGS Market (by Throughput), by Volume
  - 2.1.6.2. Europe NGS Market (by End User)
    - 2.1.6.2.1. Europe NGS Market (Academic and Research Institutes, by Offering)
    - 2.1.6.2.2. Europe NGS Market (Clinical Laboratories, by Offering)
    - 2.1.6.2.3. Europe NGS Market (Pharmaceutical and Biotechnology Companies, by Offering)
    - 2.1.6.2.4. Europe NGS Market (Other End Users, by Offering)
  - 2.1.6.3. Europe NGS Market (by Technology Type)
  - 2.1.6.4. Europe NGS Market (by Application)
    - 2.1.6.4.1. Europe NGS Market (Application, by Clinical Diagnostics)
    - 2.1.6.4.2. Europe NGS Market (Application, by Research)
  - 2.1.6.5. Europe NGS Market (by Country)
    - 2.1.6.5.1. Germany
      - 2.1.6.5.1.1. Market Dynamics
      - 2.1.6.5.1.2. Market Sizing and Forecast, by Value
      - 2.1.6.5.1.2.1. Germany NGS Market (by Offering), by Value
      - 2.1.6.5.1.2.1.1. Germany NGS Market (Equipment), by Value
      - 2.1.6.5.1.2.1.1.1. Germany NGS Market (Equipment, by Company), by Value
      - 2.1.6.5.1.2.1.2. Germany NGS Market (Equipment), by Volume
    - 2.1.6.5.2. U.K.
      - 2.1.6.5.2.1. Market Dynamics
      - 2.1.6.5.2.2. Market Sizing and Forecast, by Value
      - 2.1.6.5.2.2.1. U.K. NGS Market (by Offering), by Value
      - 2.1.6.5.2.2.1.1. U.K. NGS Market (Equipment), by Value
      - 2.1.6.5.2.2.1.1.1. U.K. NGS Market (Equipment, by Company), by Value
      - 2.1.6.5.2.2.1.2. U.K. NGS Market (Equipment), by Volume
    - 2.1.6.5.3. France
      - 2.1.6.5.3.1. Market Dynamics
      - 2.1.6.5.3.2. Market Sizing and Forecast, by Value
      - 2.1.6.5.3.2.1. France NGS Market (by Offering), by Value
      - 2.1.6.5.3.2.1.1. France NGS Market (Equipment), by Value
      - 2.1.6.5.3.2.1.1.1. France NGS Market (Equipment, by Company), by Value
      - 2.1.6.5.3.2.1.2. France NGS Market (Equipment), by Volume
    - 2.1.6.5.4. Italy
      - 2.1.6.5.4.1. Market Dynamics
      - 2.1.6.5.4.2. Market Sizing and Forecast, by Value
      - 2.1.6.5.4.2.1. Italy NGS Market (by Offering), by Value
      - 2.1.6.5.4.2.1.1. Italy NGS Market (Equipment), by Value
      - 2.1.6.5.4.2.1.1.1. Italy NGS Market (Equipment, by Company), by Value
      - 2.1.6.5.4.2.1.2. Italy NGS Market (Equipment), by Volume
    - 2.1.6.5.5. Spain
      - 2.1.6.5.5.1. Market Dynamics
      - 2.1.6.5.5.2. Market Sizing and Forecast, by Value
      - 2.1.6.5.5.2.1. Spain NGS Market (by Offering), by Value
      - 2.1.6.5.5.2.1.1. Spain NGS Market (Equipment), by Value
      - 2.1.6.5.5.2.1.1.1. Spain NGS Market (Equipment, by Company), by Value
      - 2.1.6.5.5.2.1.2. Spain NGS Market (Equipment), by Volume
    - 2.1.6.5.6. Rest-of-Europe
      - 2.1.6.5.6.1. Market Dynamics
      - 2.1.6.5.6.2. Market Sizing and Forecast, by Value
      - 2.1.6.5.6.2.1. Rest-of-Europe NGS Market (by Offering), by Value
      - 2.1.6.5.6.2.1.1. Rest-of-Europe NGS Market (Equipment), by Value
      - 2.1.6.5.6.2.1.1.1. Rest-of-Europe NGS Market (Equipment, by Company), by Value
      - 2.1.6.5.6.2.1.2. Rest-of-Europe NGS Market (Equipment), by Volume

3. Markets - Competitive Benchmarking & Company Profiles

3.1. Competitive Landscape
- 3.1.1. Overview
- 3.1.2. Corporate Strategies
  - 3.1.2.1. Mergers and Acquisitions
  - 3.1.2.2. Synergistic Activities
  - 3.1.2.3. Business Expansions and Funding
- 3.1.3. Business Strategies
  - 3.1.3.1. Product Launches/Upgradations/Approvals
3.2. Market Share Analysis
3.3. Growth-Share Analysis for the NGS Market (by End User)
3.4. Growth-Share Analysis for the NGS Market (by Throughput)
3.5. Company Profiles
- 3.5.1. Oxford Nanopore Technologies plc.
  - 3.5.1.1. Company Overview
  - 3.5.1.2. Role of Oxford Nanopore Technologies plc. in the NGS Market
  - 3.5.1.3. Recent Developments
  - 3.5.1.4. Financials
  - 3.5.1.5. Target Customers
  - 3.5.1.6. Analyst Perception
- 3.5.2. Qiagen N.V.
  - 3.5.2.1. Company Overview
  - 3.5.2.2. Role of Qiagen N.V. in the NGS Market
  - 3.5.2.3. Financials
  - 3.5.2.4. Recent Developments
  - 3.5.2.5. Target Customers
  - 3.5.2.6. Analyst's Perspective
- 3.5.3. F. Hoffmann-La Roche Ltd
  - 3.5.3.1. Company Overview
  - 3.5.3.2. Role of F. Hoffmann-La Roche Ltd in the NGS Market
  - 3.5.3.3. Financials
  - 3.5.3.4. Recent Developments
  - 3.5.3.5. Target Customers
  - 3.5.3.6. Analyst's Perspective
- 3.5.4. Centogene N.V.
  - 3.5.4.1. Company Overview
  - 3.5.4.2. Role of Centogene N.V. in the NGS Market
  - 3.5.4.3. Financials
  - 3.5.4.4. Recent Developments
  - 3.5.4.5. Target Customers
  - 3.5.4.6. Analyst's Perspective
3.6. Emerging Company Snapshots
- 3.6.1. Alithea Genomics
  - 3.6.1.1. Company Overview
  - 3.6.1.2. Role of Alithea Genomics in the NGS Market
  - 3.6.1.3. Recent Developments